Oruka Therapeutics (NASDAQ:ORKA) Releases Earnings Results, Beats Estimates By $0.04 EPS

Oruka Therapeutics (NASDAQ:ORKA) issued its quarterly earnings results on Wednesday. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04, FiscalAI reports.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock traded down $1.47 during trading hours on Wednesday, reaching $63.18. The company had a trading volume of 947,406 shares, compared to its average volume of 2,397,652. Oruka Therapeutics has a one year low of $8.91 and a one year high of $91.00. The business has a fifty day simple moving average of $54.01 and a 200 day simple moving average of $38.92.

Insiders Place Their Bets

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $66.12, for a total value of $462,840.00. Following the completion of the transaction, the insider owned 33,377 shares of the company’s stock, valued at approximately $2,206,887.24. This represents a 17.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 23,765 shares of company stock worth $1,089,745. 23.49% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Large investors have recently modified their holdings of the company. Invesco Ltd. grew its stake in Oruka Therapeutics by 777.1% during the fourth quarter. Invesco Ltd. now owns 143,121 shares of the company’s stock valued at $4,338,000 after acquiring an additional 126,803 shares in the last quarter. Virtus Investment Advisers LLC purchased a new stake in Oruka Therapeutics in the 4th quarter worth approximately $267,000. RTW Investments LP boosted its holdings in Oruka Therapeutics by 5.8% in the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after purchasing an additional 112,499 shares during the period. Millennium Management LLC bought a new position in Oruka Therapeutics in the 4th quarter valued at $1,780,000. Finally, Janus Henderson Group PLC purchased a new position in shares of Oruka Therapeutics during the 4th quarter valued at $367,000. 56.44% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ORKA. Wedbush set a $165.00 target price on Oruka Therapeutics in a research report on Monday, April 27th. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, April 30th. Barclays lifted their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. Finally, Stifel Nicolaus upped their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.80.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.